Onglyza heart failure lawsuits expand

Onglyza diabetes drug lawsuits are growing in federal court, with the number of claims recently passing the 100 mark. The pharmaceutical legal team at Jones Ward is playing a leading role in these cases. Alex Davis, one of the firm’s partners, filed one of the first Onglyza heart failure lawsuits in federal court in 2016.

Ongylza and Kombiglyze XR are used by more than 100,00 Type 2 Diabetes patients in the United States. The two drugs have been on the domestic market since 2010. In April 2016 the FDA issued a safety warning linking these saxagliptin drugs to heart failure, especially in patients who already suffer from heart or kidney disease.

The lawsuits against Bristol-Myers Squibb and AstraZeneca are now part of MDL 2809, a common procedure in mass tort cases that allows the parties to litigate certain pre-trial matters in front of a single judge in a more efficient and cost effective manner. An MDL is different than a class action, because the lawsuits remain individual cases, and eventually could be remanded back to their original jurisdictions for trial. The judge for the MDL for Onglyza is Hon. Karen Caldwell, in the Eastern District of Kentucky.

Onglyza Heart Failure Injuries

Heart failure means the heart is not pumping enough blood. It can be a deadly condition. Health professionals are worried about reports of increased risk of heart failure for users of these incretin-based therapies. The lawsuits claim that drug companies such as Bristol-Myers Squibb and AstraZeneca failed to warn of the risk. Onglyza and Kombiglyze XR are both prescribed for Type 2 diabetes.

Scientific data show a statistically significant increase in the risk of heart failure with Onglyza. After receiving and reviewing disturbing findings from a clinical trial called SAVOR, the FDA requested the raw trial data, free from manipulation by Defendants, and performed its own analysis of the SAVOR data. Following the FDA’s detailed analysis and review of the SAVOR safety signal for hospitalization for heart failure, the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee convened and voted 14 to 1 for the FDA to order a heart failure warning for these Saxagliptin drugs.

Jones Ward is currently evaluating potential Onglyza and Kombiglyze XR lawsuits. If you or someone you care about took Onglyza or Kombiglyze XR and was diagnosed with heart failure, our attorneys may be able to help you obtain financial compensation for any injury-related damages you incurred, including medical expenses, lost wages, pain and suffering, and more. Fill our our form today or call us toll free at 888-595-2922 for a free legal consultation. You may also email Attorney Alex Davis at alex@jonesward.com.

 

Sorry, comments are closed for this post.